Related Experiment Video

Updated: Aug 31, 2025

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

9.8K

[Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia]

Ismael F Aomar-Millán1, Georgette Fatoul-Del Pino2, Úrsula Torres-Parejo3

  • 1Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, España; Instituto de Investigación Biosanitaria ibs.Granada, Granada, España.

Medicina Clinica
|August 20, 2022
PubMed
Abstract

Insights

Weight-adjusted methylprednisolone significantly reduced mortality and ICU admissions for severe SARS-CoV-2 pneumonia compared to dexamethasone. This finding offers critical insights for optimizing COVID-19 treatment protocols.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • The optimal corticosteroid regimen for moderate-severe SARS-CoV-2 pneumonia remains a key clinical question.
  • The Recovery study suggested dexamethasone efficacy, but real-world comparative data is essential.

Purpose of the Study:

  • To compare 30-day mortality and ICU admission rates between dexamethasone and weight-adjusted methylprednisolone in severe SARS-CoV-2 pneumonia.
  • To evaluate the comparative effectiveness of two corticosteroid treatments in hospitalized COVID-19 patients.

Main Methods:

  • Retrospective cohort study involving 145 patients with moderate-severe SARS-CoV-2 pneumonia.
  • Comparison of outcomes between patients receiving dexamethasone (6 mg/day) and weight-adjusted methylprednisolone.
  • Statistical analysis including hazard ratios adjusted for key demographic and clinical variables.

Main Results:

  • The dexamethasone group had significantly higher mortality (32.3% vs. 10%, p<0.001) and ICU admission rates (44.6% vs. 2.5%, p<0.001).
  • Adjusted hazard ratios indicated a 2.189-fold increased risk of mortality and a 10.589-fold increased risk of ICU admission with dexamethasone versus methylprednisolone.
  • No significant baseline differences were noted, though the methylprednisolone group had higher initial qSOFA scores.

Conclusions:

  • Weight-adjusted methylprednisolone was associated with significantly lower mortality and ICU admission compared to dexamethasone in severe COVID-19 pneumonia.
  • These findings suggest that weight-adjusted methylprednisolone may be a more effective treatment strategy for this patient population.
Keywords:
COVID-19DexametasonaDexamethasoneMethylprednisoloneMetilprednisolonaNeumoníaPneumoniaRECOVERYSARS-CoV-2

More Related Videos

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia04:59

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

Published on: May 30, 2025

473
Intratracheal Administration of Dry Powder Formulation in Mice07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

10.8K

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
284
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
376
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
329
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
365
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
292
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
434